PAhR Therapeutics is a clinical-stage company focused on developing novel mechanisms for the treatment of pulmonary arterial hypertension (PAH)

7.28.2025 | Business Wire

Pahr Therapeutics raises $14 million seed financing to pursue innovative treatments for Pulmonary Arterial Hypertension

Funding round led by RA Capital Management, AN Venture Partners, and UTEC